Found 52 Enz. Inhib. hit(s) with Target = 'Potassium/sodium hyperpolarization-activated cyclic nucleotide-gated channel 4'
TargetPotassium/sodium hyperpolarization-activated cyclic nucleotide-gated channel 4(Homo sapiens (Human))
Johnson & Johnson Pharmaceutical Research & Development
Curated by ChEMBL
Johnson & Johnson Pharmaceutical Research & Development
Curated by ChEMBL
Affinity DataIC50: 31.6nMAssay Description:Inhibition of human HCN4 heterologously expressed in HEK-293 cells after 30 mins by VIPR assayMore data for this Ligand-Target Pair
TargetPotassium/sodium hyperpolarization-activated cyclic nucleotide-gated channel 4(Homo sapiens (Human))
Johnson & Johnson Pharmaceutical Research & Development
Curated by ChEMBL
Johnson & Johnson Pharmaceutical Research & Development
Curated by ChEMBL
Affinity DataIC50: 158nMAssay Description:Inhibition of human HCN4 heterologously expressed in HEK-293 cells after 30 mins by VIPR assayMore data for this Ligand-Target Pair
TargetPotassium/sodium hyperpolarization-activated cyclic nucleotide-gated channel 4(Homo sapiens (Human))
Johnson & Johnson Pharmaceutical Research & Development
Curated by ChEMBL
Johnson & Johnson Pharmaceutical Research & Development
Curated by ChEMBL
Affinity DataIC50: 316nMAssay Description:Inhibition of human HCN4 heterologously expressed in HEK-293 cells after 30 mins by VIPR assayMore data for this Ligand-Target Pair
TargetPotassium/sodium hyperpolarization-activated cyclic nucleotide-gated channel 4(Homo sapiens (Human))
Johnson & Johnson Pharmaceutical Research & Development
Curated by ChEMBL
Johnson & Johnson Pharmaceutical Research & Development
Curated by ChEMBL
Affinity DataIC50: 316nMAssay Description:Inhibition of human HCN4 heterologously expressed in HEK-293 cells after 30 mins by VIPR assayMore data for this Ligand-Target Pair
TargetPotassium/sodium hyperpolarization-activated cyclic nucleotide-gated channel 4(Homo sapiens (Human))
Johnson & Johnson Pharmaceutical Research & Development
Curated by ChEMBL
Johnson & Johnson Pharmaceutical Research & Development
Curated by ChEMBL
Affinity DataIC50: 794nMAssay Description:Inhibition of human HCN4 heterologously expressed in HEK-293 cells after 30 mins by VIPR assayMore data for this Ligand-Target Pair
TargetPotassium/sodium hyperpolarization-activated cyclic nucleotide-gated channel 4(Homo sapiens (Human))
Johnson & Johnson Pharmaceutical Research & Development
Curated by ChEMBL
Johnson & Johnson Pharmaceutical Research & Development
Curated by ChEMBL
Affinity DataIC50: 794nMAssay Description:Inhibition of human HCN4 heterologously expressed in HEK-293 cells after 30 mins by VIPR assayMore data for this Ligand-Target Pair
TargetPotassium/sodium hyperpolarization-activated cyclic nucleotide-gated channel 4(Homo sapiens (Human))
Johnson & Johnson Pharmaceutical Research & Development
Curated by ChEMBL
Johnson & Johnson Pharmaceutical Research & Development
Curated by ChEMBL
Affinity DataIC50: 794nMAssay Description:Inhibition of human HCN4 heterologously expressed in HEK-293 cells after 30 mins by VIPR assayMore data for this Ligand-Target Pair
TargetPotassium/sodium hyperpolarization-activated cyclic nucleotide-gated channel 4(Homo sapiens (Human))
Johnson & Johnson Pharmaceutical Research & Development
Curated by ChEMBL
Johnson & Johnson Pharmaceutical Research & Development
Curated by ChEMBL
Affinity DataIC50: 1.26E+3nMAssay Description:Inhibition of human HCN4 heterologously expressed in HEK-293 cells after 30 mins by VIPR assayMore data for this Ligand-Target Pair
TargetPotassium/sodium hyperpolarization-activated cyclic nucleotide-gated channel 4(Homo sapiens (Human))
Johnson & Johnson Pharmaceutical Research & Development
Curated by ChEMBL
Johnson & Johnson Pharmaceutical Research & Development
Curated by ChEMBL
Affinity DataIC50: 1.58E+3nMAssay Description:Inhibition of human HCN4 heterologously expressed in HEK-293 cells after 30 mins by VIPR assayMore data for this Ligand-Target Pair
TargetPotassium/sodium hyperpolarization-activated cyclic nucleotide-gated channel 4(Homo sapiens (Human))
Johnson & Johnson Pharmaceutical Research & Development
Curated by ChEMBL
Johnson & Johnson Pharmaceutical Research & Development
Curated by ChEMBL
Affinity DataIC50: 2.51E+3nMAssay Description:Inhibition of human HCN4 heterologously expressed in HEK-293 cells after 30 mins by VIPR assayMore data for this Ligand-Target Pair
TargetPotassium/sodium hyperpolarization-activated cyclic nucleotide-gated channel 4(Homo sapiens (Human))
Johnson & Johnson Pharmaceutical Research & Development
Curated by ChEMBL
Johnson & Johnson Pharmaceutical Research & Development
Curated by ChEMBL
Affinity DataIC50: 3.16E+3nMAssay Description:Inhibition of human HCN4 heterologously expressed in HEK-293 cells after 30 mins by VIPR assayMore data for this Ligand-Target Pair
TargetPotassium/sodium hyperpolarization-activated cyclic nucleotide-gated channel 4(Homo sapiens (Human))
Johnson & Johnson Pharmaceutical Research & Development
Curated by ChEMBL
Johnson & Johnson Pharmaceutical Research & Development
Curated by ChEMBL
Affinity DataIC50: 3.98E+3nMAssay Description:Inhibition of human HCN4 heterologously expressed in HEK-293 cells after 30 mins by VIPR assayMore data for this Ligand-Target Pair
TargetPotassium/sodium hyperpolarization-activated cyclic nucleotide-gated channel 4(Homo sapiens (Human))
Johnson & Johnson Pharmaceutical Research & Development
Curated by ChEMBL
Johnson & Johnson Pharmaceutical Research & Development
Curated by ChEMBL
Affinity DataIC50: 3.98E+3nMAssay Description:Inhibition of human HCN4 heterologously expressed in HEK-293 cells after 30 mins by VIPR assayMore data for this Ligand-Target Pair
TargetPotassium/sodium hyperpolarization-activated cyclic nucleotide-gated channel 4(Homo sapiens (Human))
Johnson & Johnson Pharmaceutical Research & Development
Curated by ChEMBL
Johnson & Johnson Pharmaceutical Research & Development
Curated by ChEMBL
Affinity DataIC50: 5.01E+3nMAssay Description:Inhibition of human HCN4 heterologously expressed in HEK-293 cells after 30 mins by VIPR assayMore data for this Ligand-Target Pair
TargetPotassium/sodium hyperpolarization-activated cyclic nucleotide-gated channel 4(Homo sapiens (Human))
Johnson & Johnson Pharmaceutical Research & Development
Curated by ChEMBL
Johnson & Johnson Pharmaceutical Research & Development
Curated by ChEMBL
Affinity DataIC50: 5.01E+3nMAssay Description:Inhibition of human HCN4 heterologously expressed in HEK-293 cells after 30 mins by VIPR assayMore data for this Ligand-Target Pair
TargetPotassium/sodium hyperpolarization-activated cyclic nucleotide-gated channel 4(Homo sapiens (Human))
Johnson & Johnson Pharmaceutical Research & Development
Curated by ChEMBL
Johnson & Johnson Pharmaceutical Research & Development
Curated by ChEMBL
Affinity DataIC50: 5.01E+3nMAssay Description:Inhibition of human HCN4 heterologously expressed in HEK-293 cells after 30 mins by VIPR assayMore data for this Ligand-Target Pair
TargetPotassium/sodium hyperpolarization-activated cyclic nucleotide-gated channel 4(Homo sapiens (Human))
Johnson & Johnson Pharmaceutical Research & Development
Curated by ChEMBL
Johnson & Johnson Pharmaceutical Research & Development
Curated by ChEMBL
Affinity DataIC50: 5.01E+3nMAssay Description:Inhibition of human HCN4 heterologously expressed in HEK-293 cells after 30 mins by VIPR assayMore data for this Ligand-Target Pair
TargetPotassium/sodium hyperpolarization-activated cyclic nucleotide-gated channel 4(Homo sapiens (Human))
Johnson & Johnson Pharmaceutical Research & Development
Curated by ChEMBL
Johnson & Johnson Pharmaceutical Research & Development
Curated by ChEMBL
Affinity DataIC50: 6.31E+3nMAssay Description:Inhibition of human HCN4 heterologously expressed in HEK-293 cells after 30 mins by VIPR assayMore data for this Ligand-Target Pair
TargetPotassium/sodium hyperpolarization-activated cyclic nucleotide-gated channel 4(Homo sapiens (Human))
Johnson & Johnson Pharmaceutical Research & Development
Curated by ChEMBL
Johnson & Johnson Pharmaceutical Research & Development
Curated by ChEMBL
Affinity DataIC50: >1.00E+4nMAssay Description:Inhibition of human HCN4More data for this Ligand-Target Pair
TargetPotassium/sodium hyperpolarization-activated cyclic nucleotide-gated channel 4(Homo sapiens (Human))
Johnson & Johnson Pharmaceutical Research & Development
Curated by ChEMBL
Johnson & Johnson Pharmaceutical Research & Development
Curated by ChEMBL
Affinity DataIC50: 2.00E+4nMAssay Description:Inhibition of human HCN4 heterologously expressed in HEK-293 cells after 30 mins by VIPR assayMore data for this Ligand-Target Pair
TargetPotassium/sodium hyperpolarization-activated cyclic nucleotide-gated channel 4(Homo sapiens (Human))
Johnson & Johnson Pharmaceutical Research & Development
Curated by ChEMBL
Johnson & Johnson Pharmaceutical Research & Development
Curated by ChEMBL
Affinity DataIC50: 2.00E+4nMAssay Description:Inhibition of human HCN4 heterologously expressed in HEK-293 cells after 30 mins by VIPR assayMore data for this Ligand-Target Pair
TargetPotassium/sodium hyperpolarization-activated cyclic nucleotide-gated channel 4(Homo sapiens (Human))
Johnson & Johnson Pharmaceutical Research & Development
Curated by ChEMBL
Johnson & Johnson Pharmaceutical Research & Development
Curated by ChEMBL
Affinity DataIC50: 3.16E+4nMAssay Description:Inhibition of human HCN4 heterologously expressed in HEK-293 cells after 30 mins by VIPR assayMore data for this Ligand-Target Pair
TargetPotassium/sodium hyperpolarization-activated cyclic nucleotide-gated channel 4(Homo sapiens (Human))
Johnson & Johnson Pharmaceutical Research & Development
Curated by ChEMBL
Johnson & Johnson Pharmaceutical Research & Development
Curated by ChEMBL
Affinity DataIC50: >3.20E+4nMAssay Description:Inhibition of human HCN4 by Ion-work electrophysiology assayMore data for this Ligand-Target Pair
TargetPotassium/sodium hyperpolarization-activated cyclic nucleotide-gated channel 4(Homo sapiens (Human))
Johnson & Johnson Pharmaceutical Research & Development
Curated by ChEMBL
Johnson & Johnson Pharmaceutical Research & Development
Curated by ChEMBL
Affinity DataIC50: >3.20E+4nMAssay Description:Inhibition of human HCN4 by Ion-work electrophysiology assayMore data for this Ligand-Target Pair
TargetPotassium/sodium hyperpolarization-activated cyclic nucleotide-gated channel 4(Homo sapiens (Human))
Johnson & Johnson Pharmaceutical Research & Development
Curated by ChEMBL
Johnson & Johnson Pharmaceutical Research & Development
Curated by ChEMBL
Affinity DataIC50: >3.30E+4nMAssay Description:Inhibition of human HCN4 channel expressed in CHO cells by IONWORKS patch clamp assayMore data for this Ligand-Target Pair
TargetPotassium/sodium hyperpolarization-activated cyclic nucleotide-gated channel 4(Homo sapiens (Human))
Johnson & Johnson Pharmaceutical Research & Development
Curated by ChEMBL
Johnson & Johnson Pharmaceutical Research & Development
Curated by ChEMBL
Affinity DataIC50: 3.98E+4nMAssay Description:Inhibition of human HCN4 heterologously expressed in HEK-293 cells after 30 mins by VIPR assayMore data for this Ligand-Target Pair
TargetPotassium/sodium hyperpolarization-activated cyclic nucleotide-gated channel 4(Homo sapiens (Human))
Johnson & Johnson Pharmaceutical Research & Development
Curated by ChEMBL
Johnson & Johnson Pharmaceutical Research & Development
Curated by ChEMBL
Affinity DataIC50: 3.98E+4nMAssay Description:Inhibition of human HCN4 heterologously expressed in HEK-293 cells after 30 mins by VIPR assayMore data for this Ligand-Target Pair
TargetPotassium/sodium hyperpolarization-activated cyclic nucleotide-gated channel 4(Homo sapiens (Human))
Johnson & Johnson Pharmaceutical Research & Development
Curated by ChEMBL
Johnson & Johnson Pharmaceutical Research & Development
Curated by ChEMBL
Affinity DataIC50: 5.01E+4nMAssay Description:Inhibition of human HCN4 heterologously expressed in HEK-293 cells after 30 mins by VIPR assayMore data for this Ligand-Target Pair
TargetPotassium/sodium hyperpolarization-activated cyclic nucleotide-gated channel 4(Homo sapiens (Human))
Johnson & Johnson Pharmaceutical Research & Development
Curated by ChEMBL
Johnson & Johnson Pharmaceutical Research & Development
Curated by ChEMBL
Affinity DataIC50: 7.94E+4nMAssay Description:Inhibition of human HCN4 heterologously expressed in HEK-293 cells after 30 mins by VIPR assayMore data for this Ligand-Target Pair
TargetPotassium/sodium hyperpolarization-activated cyclic nucleotide-gated channel 4(Homo sapiens (Human))
Johnson & Johnson Pharmaceutical Research & Development
Curated by ChEMBL
Johnson & Johnson Pharmaceutical Research & Development
Curated by ChEMBL
Affinity DataIC50: >1.00E+5nMAssay Description:Inhibition of potassium channel HCN4 (unknown origin)More data for this Ligand-Target Pair
TargetPotassium/sodium hyperpolarization-activated cyclic nucleotide-gated channel 4(Homo sapiens (Human))
Johnson & Johnson Pharmaceutical Research & Development
Curated by ChEMBL
Johnson & Johnson Pharmaceutical Research & Development
Curated by ChEMBL
Affinity DataIC50: >1.00E+5nMAssay Description:Inhibition of potassium channel HCN4 (unknown origin)More data for this Ligand-Target Pair
TargetPotassium/sodium hyperpolarization-activated cyclic nucleotide-gated channel 4(Homo sapiens (Human))
Johnson & Johnson Pharmaceutical Research & Development
Curated by ChEMBL
Johnson & Johnson Pharmaceutical Research & Development
Curated by ChEMBL
Affinity DataIC50: >1.00E+5nMAssay Description:Inhibition of human HCN4 expressed in CHO cells by automated patch clamp assayMore data for this Ligand-Target Pair
TargetPotassium/sodium hyperpolarization-activated cyclic nucleotide-gated channel 4(Homo sapiens (Human))
Johnson & Johnson Pharmaceutical Research & Development
Curated by ChEMBL
Johnson & Johnson Pharmaceutical Research & Development
Curated by ChEMBL
Affinity DataIC50: 1.00E+5nMAssay Description:Inhibition of human HCN4 heterologously expressed in HEK-293 cells after 30 mins by VIPR assayMore data for this Ligand-Target Pair
TargetPotassium/sodium hyperpolarization-activated cyclic nucleotide-gated channel 4(Homo sapiens (Human))
Johnson & Johnson Pharmaceutical Research & Development
Curated by ChEMBL
Johnson & Johnson Pharmaceutical Research & Development
Curated by ChEMBL
Affinity DataIC50: 1.58E+5nMAssay Description:Inhibition of human HCN4 heterologously expressed in HEK-293 cells after 30 mins by VIPR assayMore data for this Ligand-Target Pair
TargetPotassium/sodium hyperpolarization-activated cyclic nucleotide-gated channel 4(Homo sapiens (Human))
Johnson & Johnson Pharmaceutical Research & Development
Curated by ChEMBL
Johnson & Johnson Pharmaceutical Research & Development
Curated by ChEMBL
Affinity DataIC50: >2.00E+5nMAssay Description:Inhibition of human HCN4 heterologously expressed in HEK-293 cells after 30 mins by VIPR assayMore data for this Ligand-Target Pair
TargetPotassium/sodium hyperpolarization-activated cyclic nucleotide-gated channel 4(Homo sapiens (Human))
Johnson & Johnson Pharmaceutical Research & Development
Curated by ChEMBL
Johnson & Johnson Pharmaceutical Research & Development
Curated by ChEMBL
Affinity DataIC50: >2.00E+5nMAssay Description:Inhibition of human HCN4 heterologously expressed in HEK-293 cells after 30 mins by VIPR assayMore data for this Ligand-Target Pair
TargetPotassium/sodium hyperpolarization-activated cyclic nucleotide-gated channel 4(Homo sapiens (Human))
Johnson & Johnson Pharmaceutical Research & Development
Curated by ChEMBL
Johnson & Johnson Pharmaceutical Research & Development
Curated by ChEMBL
Affinity DataIC50: >2.00E+5nMAssay Description:Inhibition of human HCN4 heterologously expressed in HEK-293 cells after 30 mins by VIPR assayMore data for this Ligand-Target Pair
TargetPotassium/sodium hyperpolarization-activated cyclic nucleotide-gated channel 4(Homo sapiens (Human))
Johnson & Johnson Pharmaceutical Research & Development
Curated by ChEMBL
Johnson & Johnson Pharmaceutical Research & Development
Curated by ChEMBL
Affinity DataIC50: >2.00E+5nMAssay Description:Inhibition of human HCN4 heterologously expressed in HEK-293 cells after 30 mins by VIPR assayMore data for this Ligand-Target Pair
TargetPotassium/sodium hyperpolarization-activated cyclic nucleotide-gated channel 4(Homo sapiens (Human))
Johnson & Johnson Pharmaceutical Research & Development
Curated by ChEMBL
Johnson & Johnson Pharmaceutical Research & Development
Curated by ChEMBL
Affinity DataIC50: >2.00E+5nMAssay Description:Inhibition of human HCN4 heterologously expressed in HEK-293 cells after 30 mins by VIPR assayMore data for this Ligand-Target Pair
TargetPotassium/sodium hyperpolarization-activated cyclic nucleotide-gated channel 4(Homo sapiens (Human))
Johnson & Johnson Pharmaceutical Research & Development
Curated by ChEMBL
Johnson & Johnson Pharmaceutical Research & Development
Curated by ChEMBL
Affinity DataIC50: >2.00E+5nMAssay Description:Inhibition of human HCN4 heterologously expressed in HEK-293 cells after 30 mins by VIPR assayMore data for this Ligand-Target Pair
TargetPotassium/sodium hyperpolarization-activated cyclic nucleotide-gated channel 4(Homo sapiens (Human))
Johnson & Johnson Pharmaceutical Research & Development
Curated by ChEMBL
Johnson & Johnson Pharmaceutical Research & Development
Curated by ChEMBL
Affinity DataIC50: >2.00E+5nMAssay Description:Inhibition of human HCN4 heterologously expressed in HEK-293 cells after 30 mins by VIPR assayMore data for this Ligand-Target Pair
TargetPotassium/sodium hyperpolarization-activated cyclic nucleotide-gated channel 4(Homo sapiens (Human))
Johnson & Johnson Pharmaceutical Research & Development
Curated by ChEMBL
Johnson & Johnson Pharmaceutical Research & Development
Curated by ChEMBL
Affinity DataEC50: 1.36E+5nMAssay Description:Blockade of human HCN4 expressed in HEK293 cells at -120 f-current amplitude by patch-clamp electrophysiological assayMore data for this Ligand-Target Pair
TargetPotassium/sodium hyperpolarization-activated cyclic nucleotide-gated channel 4(Homo sapiens (Human))
Johnson & Johnson Pharmaceutical Research & Development
Curated by ChEMBL
Johnson & Johnson Pharmaceutical Research & Development
Curated by ChEMBL
Affinity DataEC50: 1.04E+5nMAssay Description:Blockade of human HCN4 expressed in HEK293 cells at -120 f-current amplitude by patch-clamp electrophysiological assayMore data for this Ligand-Target Pair
TargetPotassium/sodium hyperpolarization-activated cyclic nucleotide-gated channel 4(Homo sapiens (Human))
Johnson & Johnson Pharmaceutical Research & Development
Curated by ChEMBL
Johnson & Johnson Pharmaceutical Research & Development
Curated by ChEMBL
Affinity DataEC50: 3.16E+4nMAssay Description:Blockade of human HCN4 expressed in HEK293 cells at -120 f-current amplitude by patch-clamp electrophysiological assayMore data for this Ligand-Target Pair
TargetPotassium/sodium hyperpolarization-activated cyclic nucleotide-gated channel 4(Homo sapiens (Human))
Johnson & Johnson Pharmaceutical Research & Development
Curated by ChEMBL
Johnson & Johnson Pharmaceutical Research & Development
Curated by ChEMBL
Affinity DataEC50: 2.49E+4nMAssay Description:Blockade of human HCN4 expressed in HEK293 cells at -120 f-current amplitude by patch-clamp electrophysiological assayMore data for this Ligand-Target Pair
TargetPotassium/sodium hyperpolarization-activated cyclic nucleotide-gated channel 4(Homo sapiens (Human))
Johnson & Johnson Pharmaceutical Research & Development
Curated by ChEMBL
Johnson & Johnson Pharmaceutical Research & Development
Curated by ChEMBL
Affinity DataEC50: 3.98E+3nMAssay Description:Inhibition of human HCN4 expressed in HEK293 cells assessed as reduction in hyperpolarization activated current at holding potential of -80 mV by pat...More data for this Ligand-Target Pair
TargetPotassium/sodium hyperpolarization-activated cyclic nucleotide-gated channel 4(Homo sapiens (Human))
Johnson & Johnson Pharmaceutical Research & Development
Curated by ChEMBL
Johnson & Johnson Pharmaceutical Research & Development
Curated by ChEMBL
Affinity DataEC50: 4.28E+3nMAssay Description:Blockade of human HCN4 expressed in HEK293 cells at -120 f-current amplitude by patch-clamp electrophysiological assayMore data for this Ligand-Target Pair
TargetPotassium/sodium hyperpolarization-activated cyclic nucleotide-gated channel 4(Homo sapiens (Human))
Johnson & Johnson Pharmaceutical Research & Development
Curated by ChEMBL
Johnson & Johnson Pharmaceutical Research & Development
Curated by ChEMBL
Affinity DataEC50: 7.14E+3nMAssay Description:Blockade of human HCN4 expressed in HEK293 cells at -120 f-current amplitude by patch-clamp electrophysiological assayMore data for this Ligand-Target Pair
TargetPotassium/sodium hyperpolarization-activated cyclic nucleotide-gated channel 4(Homo sapiens (Human))
Johnson & Johnson Pharmaceutical Research & Development
Curated by ChEMBL
Johnson & Johnson Pharmaceutical Research & Development
Curated by ChEMBL
Affinity DataEC50: 7.23E+3nMAssay Description:Blockade of human HCN4 expressed in HEK293 cells at -120 f-current amplitude by patch-clamp electrophysiological assayMore data for this Ligand-Target Pair
TargetPotassium/sodium hyperpolarization-activated cyclic nucleotide-gated channel 4(Homo sapiens (Human))
Johnson & Johnson Pharmaceutical Research & Development
Curated by ChEMBL
Johnson & Johnson Pharmaceutical Research & Development
Curated by ChEMBL
Affinity DataEC50: 8.57E+3nMAssay Description:Blockade of human HCN4 expressed in HEK293 cells at -120 f-current amplitude by patch-clamp electrophysiological assayMore data for this Ligand-Target Pair